Madrigal Pharmaceuticals (MDGL) Net Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Madrigal Pharmaceuticals | 14.44 Bn | 14.20 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.81% |
| Dec 31, 2025 | 0.23% |
| Sep 30, 2025 | -13.90% |
| Jun 30, 2025 | 2.97% |
| Mar 31, 2025 | -15.18% |
| Dec 31, 2024 | -16.46% |
| Sep 30, 2024 | -37.93% |
| Jun 30, 2024 | -50.47% |
| Mar 31, 2024 | -57.80% |
| Dec 31, 2023 | -57.78% |
| Sep 30, 2023 | -63.26% |
| Jun 30, 2023 | -66.73% |
| Mar 31, 2023 | -64.60% |
| Dec 31, 2022 | -58.11% |
| Sep 30, 2022 | -57.18% |
| Jun 30, 2022 | -53.33% |
| Mar 31, 2022 | -57.16% |
| Dec 31, 2021 | -52.98% |
| Sep 30, 2021 | -35.07% |
| Jun 30, 2021 | -84.83% |
| Mar 31, 2021 | -96.78% |
| Dec 31, 2020 | -41.19% |
| Sep 30, 2020 | -100.26% |
| Jun 30, 2020 | -19.93% |
| Mar 31, 2020 | -11.78% |
| Dec 31, 2019 | -6.39% |
| Sep 30, 2019 | -1.42% |
| Jun 30, 2019 | 2.44% |
| Mar 31, 2019 | 8.53% |
| Dec 31, 2018 | 13.84% |
| Sep 30, 2018 | 17.68% |
| Jun 30, 2018 | 21.81% |
| Mar 31, 2018 | 21.04% |
| Dec 31, 2017 | 13.66% |
| Sep 30, 2017 | 10.81% |
| Jun 30, 2017 | 10.60% |
| Mar 31, 2017 | 16.80% |
| Dec 31, 2016 | 6.43% |
| Sep 30, 2016 | -1.97% |
| Jun 30, 2016 | 25.56% |
| Mar 31, 2016 | 30.95% |
| Dec 31, 2015 | -3.61% |
| Sep 30, 2015 | 29.40% |
| Jun 30, 2015 | -16.89% |